Company Overview of Dermira, Inc.
Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company’s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which is in Phase III clinical trial for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and DRM01, a small-molecule sebum inhibitor, which is in Phase IIb clinical trial for the treatment of a...
275 Middlefield Road
Menlo Park, CA 94025
Founded in 2010
Key Executives for Dermira, Inc.
Co-Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $465.0K
Co-Founder, Chief Medical Officer, Director and Member of Science & Technology Committee
Total Annual Compensation: $350.0K
Chief Financial Officer and Chief Operating Officer
Total Annual Compensation: $355.0K
Compensation as of Fiscal Year 2015.
Dermira, Inc. Key Developments
Dermira, Inc Appoints of Lori Lyons-Williams as Chief Commercial Officer
Jan 5 17
Dermira, Inc. announced the appointment of Lori Lyons-Williams as Chief Commercial Officer. In this new role, Lori will be responsible for developing and implementing the commercial strategy for Dermira’s Phase 3 product candidates: CIMZIA® (certolizumab pegol), in development in collaboration with UCB Pharma S.A. Prior to joining Dermira, she spent 15 years in positions of increasing responsibility within the sales and marketing organization at Allergan, most recently as Vice President, Sales & Marketing for the Urology franchise.
Dermira Initiates Phase 3 Clinical Program in Acne
Jan 3 17
Dermira, Inc. announced dosing of the first patients in the Phase 3 program evaluating the safety and efficacy of olumacostat glasaretil (formerly DRM01), a novel, small molecule designed to reduce sebum production following topical application, in patients with acne vulgaris. The start of the olumacostat glasaretil Phase 3 clinical program is an important milestone for Dermira and puts one step closer to potentially offering patients a new, topical treatment option that targets an underlying cause of acne that is not addressed by available topical therapies. The Phase 3 clinical program consists of two randomized, multi-center, double-blind, parallel-group, vehicle-controlled trials, CLAREOS-1 and CLAREOS-2, designed to assess the safety and efficacy of olumacostat glasaretil compared to vehicle to support a potential New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). The program is expected to enroll a total of approximately 1,400 patients ages nine and older with moderate-to-severe acne vulgaris at approximately 100 sites in the United States, Canada and Australia. In each trial, approximately 700 patients will be randomized and instructed to apply either olumacostat glasaretil at a concentration of 5.0% or vehicle, in a 2:1 fashion, twice daily to the face for 12 weeks.
Dermira, Inc. Appoints Emmanuel Caeymaex as Class II Director
Dec 28 16
Dermira, Inc. elected Emmanuel Caeymaex as a Class II director, effective January 1, 2017 to hold office for a term expiring at the 2019 annual meeting of stockholders.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|